Cargando…
Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study
OBJECTIVES: British Thoracic Society guidelines recommend clarithromycin in addition to beta-lactam antibiotics for patients with community-acquired pneumonia and CURB-65 score 2–5. Intravenous therapy is commonly used but there are few data on whether oral therapy is equally effective. METHODS: Thi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471852/ https://www.ncbi.nlm.nih.gov/pubmed/28702304 http://dx.doi.org/10.1186/s41479-017-0025-2 |
_version_ | 1783244028758720512 |
---|---|
author | Rae, Nikolas Singanayagam, Aran Schembri, Stuart Chalmers, James D. |
author_facet | Rae, Nikolas Singanayagam, Aran Schembri, Stuart Chalmers, James D. |
author_sort | Rae, Nikolas |
collection | PubMed |
description | OBJECTIVES: British Thoracic Society guidelines recommend clarithromycin in addition to beta-lactam antibiotics for patients with community-acquired pneumonia and CURB-65 score 2–5. Intravenous therapy is commonly used but there are few data on whether oral therapy is equally effective. METHODS: This observational study used propensity matching to compare two groups of patients with moderate to severe community-acquired pneumonia (CURB-65 score 2–5) treated with oral (n = 226) or intravenous (n = 226) clarithromycin on admission. Outcomes were 30-day mortality, intensive care unit admission, time to clinical stability, and length of hospital stay. RESULTS: There was no significant difference in 30-day mortality (16.8% for intravenous [IV] group vs. 14.6% for oral group, hazard ratio for IV group 1.11 95% CI 0.70–1.78), ICU admission (10.6% in both groups) or complications (10.6% for IV group and 9.3% for oral group) between the groups. The time to clinical stability in both cohorts was a median of 5 days (interquartile range 3–7 days, p = 0.3). The median length of hospital stay was 8 days in the IV group (interquartile range 4–14 days) and 7 days in the oral group (interquartile range 4–13 days), p = 0.5. No other differences were observed between oral and IV groups. CONCLUSION: Where the oral route is not compromised, oral macrolides appear to be equivalent to IV in treating moderate to severe CAP. |
format | Online Article Text |
id | pubmed-5471852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54718522017-07-12 Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study Rae, Nikolas Singanayagam, Aran Schembri, Stuart Chalmers, James D. Pneumonia (Nathan) Brief Report OBJECTIVES: British Thoracic Society guidelines recommend clarithromycin in addition to beta-lactam antibiotics for patients with community-acquired pneumonia and CURB-65 score 2–5. Intravenous therapy is commonly used but there are few data on whether oral therapy is equally effective. METHODS: This observational study used propensity matching to compare two groups of patients with moderate to severe community-acquired pneumonia (CURB-65 score 2–5) treated with oral (n = 226) or intravenous (n = 226) clarithromycin on admission. Outcomes were 30-day mortality, intensive care unit admission, time to clinical stability, and length of hospital stay. RESULTS: There was no significant difference in 30-day mortality (16.8% for intravenous [IV] group vs. 14.6% for oral group, hazard ratio for IV group 1.11 95% CI 0.70–1.78), ICU admission (10.6% in both groups) or complications (10.6% for IV group and 9.3% for oral group) between the groups. The time to clinical stability in both cohorts was a median of 5 days (interquartile range 3–7 days, p = 0.3). The median length of hospital stay was 8 days in the IV group (interquartile range 4–14 days) and 7 days in the oral group (interquartile range 4–13 days), p = 0.5. No other differences were observed between oral and IV groups. CONCLUSION: Where the oral route is not compromised, oral macrolides appear to be equivalent to IV in treating moderate to severe CAP. BioMed Central 2017-02-05 /pmc/articles/PMC5471852/ /pubmed/28702304 http://dx.doi.org/10.1186/s41479-017-0025-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Brief Report Rae, Nikolas Singanayagam, Aran Schembri, Stuart Chalmers, James D. Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
title | Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
title_full | Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
title_fullStr | Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
title_full_unstemmed | Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
title_short | Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
title_sort | oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471852/ https://www.ncbi.nlm.nih.gov/pubmed/28702304 http://dx.doi.org/10.1186/s41479-017-0025-2 |
work_keys_str_mv | AT raenikolas oralversusintravenousclarithromycininmoderatetoseverecommunityacquiredpneumoniaanobservationalstudy AT singanayagamaran oralversusintravenousclarithromycininmoderatetoseverecommunityacquiredpneumoniaanobservationalstudy AT schembristuart oralversusintravenousclarithromycininmoderatetoseverecommunityacquiredpneumoniaanobservationalstudy AT chalmersjamesd oralversusintravenousclarithromycininmoderatetoseverecommunityacquiredpneumoniaanobservationalstudy |